AVI BioPharma - Investor and Analyst Breakfast Recording and Presentations

September 10, 2008 at 2:16 PM EDT

Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company

September 10, 2008

Dr. Leslie Hudson, President and CEO, AVI BioPharma
RNA–based drug discovery and development

Audio (MP3), Slides (PDF)

Professor Francesco Muntoni, Professor of Pediatric Neurology, Head of the Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK
Duchenne Muscular Dystrophy (DMD): The disease, its clinical management and future treatment

Audio Part 1 (MP3), Audio Part 2 (MP3), Slides (PDF)

Dr. Leslie Hudson
Clinical Trials of AVI–4658 and the commercial prospects for a DMD franchise

Audio (MP3), Slides (PDF)

Dr. Ryszard Kole, SVP of Discovery Research, AVI BioPharma
Directed alternative splicing mediated by novel oligomers with increased potency and bioavailability

Audio (MP3), Slides (PDF)

Benjamin D. Johnson, Engineering Manager, Global Therapeutics, a COOK Medical Company
Developing a breakthrough drug–eluting stent (DES) technology using the GTX platform and an improved application of antisense therapy: AVI–5126

Audio (MP3), Slides (PDF)

Dr. Patrick Iversen, SVP of Strategic Alliances, AVI BioPharma
Biodefense priorities for AVI and the enablement of HCV drug discovery

Audio Part 1 (MP3), Audio Part 2 (MP3), Slides (PDF)

J. David Boyle, SVP Finance and CFO, AVI BioPharma
Building an RNA–based drug discovery and development company

Audio (MP3), Slides (PDF)